Pristiq: Targeted Serotonin-Norepinephrine Reuptake for Depression
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.46 | $73.69 (0%) | 🛒 Add to cart |
| 40 | $2.35 | $98.25 $93.88 (4%) | 🛒 Add to cart |
| 60 | $2.25 | $147.38 $135.27 (8%) | 🛒 Add to cart |
| 90 | $2.18 | $221.07 $195.83 (11%) | 🛒 Add to cart |
| 120 | $2.15 | $294.76 $257.41 (13%) | 🛒 Add to cart |
| 180 | $2.11 | $442.14 $380.56 (14%) | 🛒 Add to cart |
| 270 | $2.10
Best per pill | $663.21 $566.30 (15%) | 🛒 Add to cart |
Synonyms | |||
Pristiq (desvenlafaxine) is a prescription serotonin-norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD) in adults. It functions by increasing the levels of serotonin and norepinephrine in the brain, two neurotransmitters critically involved in mood regulation. Clinical studies have demonstrated its efficacy in improving depressive symptoms, offering a well-characterized option for patients requiring pharmacologic intervention. This medication is available in extended-release tablet form, designed to provide steady-state concentration with once-daily dosing.
Features
- Active ingredient: desvenlafaxine
- Drug class: serotonin-norepinephrine reuptake inhibitor (SNRI)
- Available strengths: 25 mg, 50 mg, 100 mg extended-release tablets
- Administration: oral, once daily
- FDA-approved for major depressive disorder (MDD)
- Bioavailability: approximately 80%
- Half-life: approximately 11 hours
- Metabolism: primarily via glucuronidation and CYP3A4 to a minor extent
Benefits
- Effective reduction of core depressive symptoms, including low mood and anhedonia
- May improve energy levels and concentration due to dual reuptake inhibition
- Once-daily dosing supports adherence and consistent therapeutic levels
- Lower risk of certain pharmacokinetic drug interactions compared to some SSRIs
- Extended-release formulation minimizes peak-trough fluctuations
- Established efficacy in adult populations across multiple clinical trials
Common use
Pristiq is indicated for the treatment of major depressive disorder (MDD). It is prescribed for adults experiencing persistent depressive symptoms such as depressed mood, loss of interest or pleasure, changes in weight or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, or recurrent thoughts of death. It is not approved for use in pediatric patients.
Dosage and direction
The recommended starting dose for Pristiq is 50 mg taken orally once daily, with or without food. Tablets should be swallowed whole and not crushed, chewed, or dissolved. Dosage adjustments may be considered based on individual patient response and tolerability, up to a maximum recommended dose of 400 mg per day, though efficacy at doses above 50 mg has not been consistently demonstrated. For patients with hepatic or severe renal impairment, a dose reduction is recommended. Treatment should be periodically reevaluated to determine the need for continued therapy.
Precautions
Patients should be monitored for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy or after dose changes. Pristiq may increase the risk of bleeding; caution is advised in patients taking anticoagulants or with inherent bleeding risk. Discontinuation symptoms including dizziness, nausea, and anxiety may occur upon abrupt cessation; a gradual taper is recommended. Use with caution in patients with a history of mania/hypomania, seizures, or angle-closure glaucoma. Blood pressure should be monitored regularly due to potential increases.
Contraindications
Pristiq is contraindicated in patients with known hypersensitivity to desvenlafaxine, venlafaxine, or any excipient of the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of serotonin syndrome; at least 14 days should elapse between discontinuing an MAOI and initiation of Pristiq, and at least 7 days after stopping Pristiq before starting an MAOI.
Possible side effects
Common adverse reactions (incidence ≥5% and at least twice that of placebo) include:
- Nausea
- Dizziness
- Insomnia
- Hyperhidrosis
- Constipation
- Decreased appetite
- Anxiety
- Specific male sexual function disorders
Serious side effects may include:
- Suicidal thoughts and behaviors
- Serotonin syndrome
- Increases in blood pressure
- Abnormal bleeding
- Angle-closure glaucoma
- Hyponatremia
- Interstitial lung disease and eosinophilic pneumonia
Drug interaction
- MAOIs: risk of serious, sometimes fatal, reactions including serotonin syndrome
- Other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tramadol): increased risk of serotonin syndrome
- Drugs that interfere with hemostasis (e.g., NSAIDs, aspirin, warfarin): increased risk of bleeding
- Drugs metabolized by CYP2D6 (e.g., desipramine, risperidone): Pristiq may increase their concentrations
- Alcohol: may enhance CNS depressant effects; avoid use
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is closer to the time of the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended.
Overdose
Symptoms of overdose may include serotonin syndrome, lethargy, restlessness, hallucinations, fast heart rate, dilated pupils, confusion, seizures, coma, and changes in blood pressure. There is no specific antidote. Management involves supportive care and addressing symptoms. Gastric lavage or activated charcoal may be considered if presented early. Due to the large volume of distribution, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial.
Storage
Store Pristiq tablets at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in the original container, tightly closed, and protect from moisture. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
Clinical trial data and post-marketing surveillance indicate that Pristiq is generally well-tolerated and effective for many patients with MDD. In controlled studies, a significant proportion of patients experienced meaningful improvement in depressive symptoms compared to placebo. Some patients report positive effects on energy and motivation, while others note side effects such as nausea or insomnia, particularly during the initial weeks of treatment. Individual responses vary, and a thorough risk-benefit assessment with a healthcare provider is essential. Long-term maintenance of effect has been demonstrated in continuation-phase trials.